John D. Hooper
37 Kent Street
Woolloongabba, QLD 4102, Australia
Woolloongabba, QLD 4102, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 98 publications
Scalable Engineering of Bio-Manufactured Extracellular Vesicles for Selective Delivery in Ovarian Cancer Patient-Derived Models.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: February 05, 2026
Indocyanine Green-Labeled Antibodies Cotargeting CDCP1 and Mesothelin for Fluorescence-Guided Imaging of Pancreatic Cancer.
Journal: Molecular pharmaceutics
Published: January 19, 2026
Using targeted therapy to promote a pro-inflammatory tumour microenvironment and anti-tumour immune response in high grade serous ovarian cancer.
Journal: British journal of cancer
Published: July 24, 2025
An α-specific PI3K inhibitor improves chemotherapy efficacy by inhibiting hepatic stellate cell activation in liver cancer.
Journal: Hepatology (Baltimore, Md.)
Published: July 09, 2025
Pathogenic OTUD3 Mutations Predispose to Ulcerative Colitis Due to Barrier Dysfunction.
Journal: Cellular and molecular gastroenterology and hepatology
Published: May 14, 2025
Highlights of 2024. Broadening anti-cancer immunotherapy modalities with antibody-drug conjugates: emerging insights from clinical studies.
Journal: Immunology and cell biology
Published: March 10, 2025
Development of a high-affinity anti-ROR1 variable region for broad anti-cancer immunotherapy.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: January 08, 2025
Antigen presentation potential is variable among human ovarian tumour and syngeneic murine models and dictates pre-clinical outcomes of immunotherapy.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: November 27, 2024
Aurora B inhibition induces hyper-polyploidy and loss of long-term proliferative potential in RB and p53 defective cells.
Journal: Cell death & disease
Published: September 30, 2024
Development of a novel malignant colorectal polyp prognostic nomogram.
Journal: ANZ journal of surgery
Published: September 28, 2024
Receptor CDCP1 Is a Potential Target for Personalized Imaging and Treatment of Poor Outcome HER2+, Triple-Negative, and Metastatic ER+/HER2- Breast Cancers.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 04, 2024
Last Updated: 09/26/2026